NCT07419347
Brief summary
The objective of this study is to assess the safety, tolerability and effectiveness of 8-week Glecaprevir/Pibrentasvir (G/P) in participants taking either prescribed or illicit drugs.
Observational study
Age:
18 Years and older.
Inclusion Criteria:
- Prescribed 8 weeks of Glecaprevir/Pibrentasvir (G/P).
- Treatment-naïve (for the current infection, participants that may have had prior
infections which were resolved with treatment are considered naive for current
infection as long as they have not received any treatment for the current
infection.)
- Is concomitantly on one or more prescription medications or illicit drugs.
Exclusion Criteria:
- Treated with DAAs other than G/P.
- History of decompensated cirrhosis.
- Had Hepatitis-B virus (HBV) infection.
- Had hepatocellular carcinoma (HCC).
